Study | Year | Follow up duration | Standard dev | # of patients initlally | Freedom from AF | Freedom from AF off AAD | Death | Emergent reopening | Phrenic nerve palsy | Stroke | Major complications |
---|---|---|---|---|---|---|---|---|---|---|---|
Bisleri et al [16] | 2012 | 28.4(mean) | 1.7 | 45 | 40/45 (88.9%) | NR | 0 | 0 | 0 | 0 | 0 |
Bulava et al [17] | 2017 | 24 (final) | 0 | 70 | 64/67 (95.5%) | NR | 0 | 2/70 | 7/10 | 0 | 9/70 (12.8%) |
De Asmundis et al [18] | 2019 | 24.9 (mean) | 11.8 | 51 | 35/51 (68.6%) | 35/51 (68.6%) | 0 | 0 | 0 | 0 | 6/51 (11.8%) |
Dunnington G. et al [19] | 2021 | 36 (final) | 0 | 451 | 104/145 (72%) | 96/145 (66%) | 7/461 | 4/455 | 6/455 | 2 | 28/461 (6.1%) |
Edgerton et al [20] | 2016 | 24 (final) | 0 | 24 | 4/21 (19%) | NR | 3/24 | 0/24 | 1/24 | 2 | 5/24 |
Gersak et al [21] | 2016 | 48Â months (final) | 0 | 76 | 18/28 (64%) | 25/36 (69%) | 2/76 | 0 | 0 | 0 | 9/76 (11.8%) |
Hwang et al [22] | 2018 | 25.2 (median) | IQR 1.2–3.2 | 72 | 43/61 (70.4%) | NR | 0 | 0 | 0 | 0 | 0 |
Jan et al [23] | 2018 | 30.5 (mean) | 6.9 | 50 | 19/25 (76%) | 14/25 (58.3%) | 0 | 1/24 | 0 | 0 | 3/24 |
Kim et al [24] | 2021 | 24Â months (final) | 0 | 81 | 55/81 (67.8%) | NR | 0 | 0 | 0 | 0 | 7/81 |
Maclean et al [25] | 2020 | 30.5 (mean) | 13.3 | 43 | 25/43 (58.1%) | 14/43 (32.6%) | 0 | 1/43 | 1/43 | 0 | 5/43 |
Maesen et al [26] | 2018 | 36Â months (final) | 0 | 64 | 50/63 (79%) | 44/57 (77%) | 0 | 0 | 0 | 0 | 3/63 |
Magni et al [27] | 2021 | 24 (final) | 0 | 49 | 33/49 (67%) | NR | 0 | 1/49 | 2/49 | 0 | 2/49 |
Ma et al [28] | 2021 | 26 (mean) | 13.5 | 40 | 34/40 (85%) | NR | 0 | 0 | 0 | 0 | 0 |
Muneretto et al [29] | 2012 | 30 (mean) | NR | 36 | 33/36 (91.6%) | 28/36 (77.7%) | 0 | 0 | 0 | 0 | 0 |
Pojar et al [30] | 2019 | 24Â months | 0 | 65 | 57/65 (87.7%) | NR | 0 | 0 | 1/65 | 0 | 1/65 |
Tan et al [31] | 2021 | 29 (mean) | 12 | 50 | 35/50 (70%) | 35/50 (70%) | 0 | 0 | 0 | 0 | 6/50 |